Log In
Print this Print this

ecraprost (AS-013)

  Manage Alerts
Collapse Summary General Information
Company LTT Bio-Pharma Co. Ltd.
DescriptionSecond generation prostaglandin E1 (PGE1)
Molecular Target Prostaglandin E1 (PGE1) receptor
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationPeripheral vascular disease (PVD)
Indication DetailsTreat chronic arterial occlusion
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today